2YWP | pdb_00002ywp

Crystal Structure of CHK1 with a Urea Inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.90 Å
  • R-Value Free: 
    0.297 (Depositor) 
  • R-Value Work: 
    0.218 (Depositor) 
  • R-Value Observed: 
    0.241 (Depositor) 

wwPDB Validation 3D Report Full Report

Validation slider image for 2YWP

This is version 1.3 of the entry. See complete history

Literature

Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors

Li, G.Hasvold, L.A.Tao, Z.-F.Wang, G.T.Gwaltney II, S.L.Patel, J.Kovar, P.Credo, R.B.Chen, Z.Zhang, H.Park, C.Sham, H.L.Sowin, T.Rosenberg, S.H.Lin, N.-H.

(2006) Bioorg Med Chem Lett 16: 2293-2298

  • DOI: https://doi.org/10.1016/j.bmcl.2006.01.028
  • Primary Citation Related Structures: 
    2YWP

  • PubMed Abstract: 

    Based on the X-ray crystallography of our lead compound 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-cyanopyrazin-2-yl)urea in the checkpoint kinase 1 (Chk1) enzyme, we modified R4, and to a lesser extent, R2, and R5 of the phenyl ring, and made a variety of N-aryl-N'-pyrazinylurea Chk1 inhibitors. Enzymatic activity less than 20 nM was observed in 15 of 41 compounds. Compound 8i provided the best overall results in the cellular assays as it abrogated doxorubicin-induced cell cycle arrest (IC50=1.7 microM) and enhanced doxorubicin cytotoxicity (IC50=0.44 microM) while displaying no single agent activity.


  • Organizational Affiliation
    • Cancer Research, Global Pharmaceutical Research & Development, Abbott Laboratories, Abbott Park, IL 60064, USA. Gaoquan.Li@abbott.com

Macromolecule Content 

  • Total Structure Weight: 31.4 kDa 
  • Atom Count: 2,208 
  • Modeled Residue Count: 269 
  • Deposited Residue Count: 269 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Serine/threonine-protein kinase Chk1269Homo sapiensMutation(s): 0 
Gene Names: CHEK1CHK1
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for O14757 (Homo sapiens)
Explore O14757 
Go to UniProtKB:  O14757
PHAROS:  O14757
GTEx:  ENSG00000149554 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO14757
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
A42

Query on A42



Download:Ideal Coordinates CCD File
B [auth A]1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA
C14 H12 Cl N5 O3
URQYPXQXSVUVRG-UHFFFAOYSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
A42 BindingDB:  2YWP Ki: 10 (nM) from 1 assay(s)
IC50: 7 (nM) from 1 assay(s)

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.90 Å
  • R-Value Free:  0.297 (Depositor) 
  • R-Value Work:  0.218 (Depositor) 
  • R-Value Observed: 0.241 (Depositor) 
Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 44.863α = 90
b = 65.513β = 94.07
c = 57.84γ = 90
Software Package:
Software NamePurpose
CNXrefinement
HKL-2000data collection
HKL-2000data reduction
HKL-2000data scaling
CNXphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Released Date: 2007-05-08 
  • Deposition Author(s): Park, C.
  • This entry supersedes: 2FGA

Revision History  (Full details and data files)

  • Version 1.0: 2007-05-08
    Type: Initial release
  • Version 1.1: 2008-04-30
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance
  • Version 1.3: 2024-03-13
    Changes: Data collection, Database references, Derived calculations